Introduction
Primary sclerosing cholangitis (PSC) is a chronic liver disease where inflammation and fibrosis lead to multifocal biliary strictures. The close association with inflammatory bowel disease (IBD) is a hallmark of the condition, with IBD present in the majority of patients (Fig. 1) . 1, 2 Until the mid-1960s, most published articles were case reports. 3 The broad implementation of endoscopic retrograde cholangiography (ERC) throughout the 1970s led to increasing recognition of the condition and in 1980, three landmark papers from the US, the UK and Norway established a clinical definition. [4] [5] [6] Subsequently, the association of PSC with cholangiocarcinoma (CCA), 7 colonic neoplasia 8 and the sub-phenotypes of smallduct PSC, 9 PSC with high immunoglobulin 4 (IgG4) levels, 10, 11 and autoimmune hepatitis ''overlap syndrome" 12, 13 have been described. Disease progression and end-stage liver disease are inevitable in most patients, 14 and in 1983 liver transplantation was established as the only curative treatment option. 15 PSC recurrence after liver transplantation in some patients was noted a few years later. 16 The pathogenesis of PSC is unknown, but a number of mechanistic theories have been proposed. The concentric fibrosis around the bile ducts in PSC (Fig. 2) is found in a variety of conditions and likely represents a common final pathway for chronic bile duct injury of any cause (Box 1). Defects in mechanisms protecting against bile acid toxicity have been proposed as key players in PSC development. [17] [18] [19] The relationship with IBD has also inspired several avenues of research. 20 Passive leakage of pro-inflammatory microbial components to the portal circulation and the possibility of an antigenic trigger of microbial origin were for many years the predominant theories. 21, 22 Recruitment of gutderived T cells to the liver or an insult resulting from disturbances in the gut microbiota have also been proposed. 23, 24 We aim to describe the current understanding of PSC, emphasising recent developments in pathophysiology and clinical management.
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Environmental factors Table 1 ). The combined impact of genetic susceptibility factors on overall PSC liability is currently less than 10%, and even accounting for future gene discoveries, environmental risk likely accounts for more than 50%. (2) The relationship between the gut and the liver affection in PSC is not clear. Early theories were concerned with the possible ''leakage" of pro-inflammatory bacterial products (e.g. lipopolysaccharides, LPS) which would engage innate immune responses (e.g. by tolllike receptor signalling). The strong human leukocyte antigen (HLA) associations found in genetic studies however claim a strong involvement of adaptive immune responses, by determining which antigens can be presented to the T cell receptor (TCR). Gut derived antigens are potential triggers of these responses, and activated T cells may migrate to both the liver and gut following clonal expansion because of the overlapping adhesion molecule profiles of gut and liver endothelia (i. Anti-neutrophil cytoplasmic antibodies (ANCA) are frequently observed in PSC, 250 and may reflect B cell responses to antigens of gut origin. 22 (3) Bile is toxic, 251 and its composition is shaped by involvement of gut-microbial co-metabolism (gut-liver cross-talk). 125 Cholangiocytes are protected against bile acid toxicity by several mechanisms, one of which is the presence of a bicarbonate (HCO 3 À ) layer (''umbrella") generated by an involvement of the Na + -independent Cl À /HCO 3 À anion exchanger (AE2) and active Cl À -transporters, most notably the ATP-driven cystic fibrosis transmembrane conductance regulator (CFTR) and the Ca ++ -driven anoctamin 1 channel. 252 The bile acid receptor TGR5 is most likely expressed at the cilia on the biliary epithelium, 253 and may be involved in the regulation of CFTR. 254 Primary or secondary disturbances in bile homeostasis are hypothesised to contribute to pathogenesis of PSC, and are the basis of bile acid based therapies (e.g. ursodeoxycholic acid and norursodeoxycholic acid). (4) Several immune cells are found in the proximity of bile ducts of PSC, most notably T cells, macrophages and neutrophils, all of which are affected by the main genetic findings ( Table 1) . The exact involvement of each cell type remains unknown, but of key importance is their likely engagement and cross-talk with an activated cholangiocyte phenotype. 87, 95, 255 (5) Chronic injury converges on common mechanisms of fibrosis development involving hepatic stellate cells and portal myofibroblasts in a hitherto undefined cross-talk with cholangiocytes. 114 The key involvement of cholangiocytes in this cross-talk is given by the ''onion skin" features of biliary fibrosis in PSC, but details are unknown. (6) Liver-related complications in PSC are mainly represented by bile duct strictures, liver cirrhosis and cholangiocarcinoma. Printed with permission from Kari C. Toverud. Seminar idiopathic inflammatory conditions over the last decades, 35 either because of decreasing exposure to protective factors (''the hygiene hypothesis") or an increasing exposure to triggers and drivers. The typical PSC patient is a 30-40 year old male presenting with a diagnosis of ulcerative colitis (UC) or Crohn's colitis and abnormal hepatic biochemistries. In up to 25% of cases, patients may also have other autoimmune diseases. 36 The diagnosis of PSC may precede that of IBD, 37 which may even present after liver transplantation for PSC. 38 Conversely, PSC may present in an IBD patient even after colectomy. 4, 39 Therefore, determining which PSC patients do not have IBD is difficult. In Northern Europe and the US, approximately two-thirds of the patients have concurrent IBD. Variable frequencies have been reported in France (60%), 40 Spain (44%), 32 Turkey (43-63%), 41 Iran (62%), 42 India (50%) and Japan (34-37%). 43 It has been suggested that a distinct population of elderly patients without IBD who should be treated and studied separately may exist in Japan. 44 Some of these patients also represent cases of IgG4-associated multi-organ disease (IgG4-associated cholangitis [IAC] ), which is hard to demarcate from PSC, even in Western populations. Elevated levels of IgG4 are seen in a subset ($10%) of patients with PSC without comprehensive diagnostic features of an IgG4-associated syndrome (the HISORt criteria). 45 A Norwegian study has questioned previous epidemiological data in PSC. 46 MRC screening of 322 patients with colitis, after 20 years, identified large-duct PSC in 7.4% of patients, in whom only 2.2% had a prior diagnosis of large-duct PSC. Similar observations have been made in a UK cohort (published in abstract form only). 47 Of note, more than two-thirds of the newly diagnosed asymptomatic patients in the Norwegian study were female, suggesting that PSC occurs as commonly in females as in males, but runs a more clinically quiescent course. This is supported by data from a large multi-centre study of 7,119 patients with PSC, which showed significantly better outcomes for female patients. 48 A milder disease course has also been reported for patients with a diagnosis of Crohn's disease. 48, 49 This difference in PSC behaviour, according to clinical presentation of IBD, may also explain why rates of PSC-like changes were comparable in UC and Crohn's disease (6.8% and 9.0%, respectively) at 20 years follow-up in the Norwegian cohort. 46 While the value of identifying subclinical PSC in IBD patients can be questioned, the increased risk of colorectal malignancy and implications for surveillance colonoscopy justify a debate on whether MRC screening of patients with IBD is warranted. The increased risk of biliary cancer and colorectal cancer in PSC is firmly established and of major clinical importance (Fig. 1) . In a multi-centre study of 7,119 PSC patients, hepatobiliary malignancy was diagnosed in 10.9%. 48 This is comparable to the population-derived observations from the Netherlands (CCA diagnosed in 7% of the PSC patients; standardised incidence ratio 398, 95% CI 246-608), 34 and higher than in patients from South- 62 and should be considered part of the normal disease spectrum in otherwise typical cases, rather than excluding the diagnosis. 68, 69 Gallbladder mass lesions or polyps have been observed in 4% to 6.5% of patients with PSC, with $55-75% of these being malignant, leading to reported gallbladder cancer frequencies of 2.5% to 3.5% in the overall PSC population. 61, 62 Although a cut-off of 0.8 cm for cholecystectomy has been proposed by some authors, 65 smaller lesions may also harbour neoplasia. 70 
Aetiology and pathogenesis
A schematic overview of the predominant processes of PSC pathogenesis is shown above (Fig. 2 ). This overview is based on the various theories of PSC pathogenesis that exist. The story is not currently complete with several contradictions including: a) the lack of efficacy of immunosuppressive drugs pre-and post-liver transplant despite a proposed autoimmune aetiology, b) the progression of PSC after colectomy in the absence of a leaky gut, c) the lack of efficacy of ursodeoxycholic acid (UDCA) and the differing genetic susceptibility of PSC compared to other progressive cholestatic syndromes, despite the proposal that bile acid toxicity causes PSC. However, the clinical observations may partly reflect that these treatments have been applied too late in the disease course, for insufficient duration and/or at an inadequate dose. The pathognomonic lesion in PSC is an ''onion skin" scar, referring to concentric layers of fibrosis circumferential to the cholangiocyte lining of the bile ducts. How the cholangiocytes and a few scattered immune cells (mostly T cells, but also neutrophils and macrophages) work with hepatic stellate cells and portal myofibroblasts in the generation of this fibrous obliteration is unknown. Most importantly, the lack of understanding of PSC pathogenesis prevents the development of effective therapies. The initiating factors for the processes shown in Fig. 2 3 ). 73 The other PSC genes show associations to prototypical autoimmune diseases (e.g. type 1 diabetes and multiple sclerosis), implying that the genetic susceptibility to PSC extends into autoimmune pathophysiology beyond that represented by IBD.
There are high hopes that the genes identified will provide critical clues to PSC pathogenesis as these findings from patients are likely to be most relevant. The translational research has scarcely started (e.g. for IL2RA and CD28), and will be challenging for many risk loci, since an individual gene has not yet been assigned as causal (i.e. it is hard to determine which of a series of neighbouring genes is relevant). 83, 84 Even within robustly assigned genes, the causal genetic variant is often unknown, making it impossible to determine whether the variants increase protein function (gain-offunction) or decrease protein function (loss-offunction). Finally, development of an appropriate portfolio of experiments based upon the published literature is biased by studies of gene function that were performed without prior knowledge of a genetic association to PSC. This means tissue-and disease-specific functions may be missed, particularly those relating to cholangiocyte and biliary physiology. Nevertheless, generating hypotheses for how the individual genes identified (Table 1) are involved in PSC pathogenesis is feasible, and now provides a great opportunity for targeted pathophysiological research. The strong HLA association suggests that adaptive immune responses are involved. The HLA class I and/or class II genes are most likely responsible for the findings in PSC 85 -possibly HLA-B (class I) and DRB1 (class II). 77, 86 The HLA class I (expressed on all cells) and class II (expressed on antigenpresenting cells) molecules present potentially antigenic peptides, derived from intracellular and extracellular sources, respectively, to the T cell receptor (TCR) on CD8 and CD4 positive T cells. In PSC and most other HLA associated diseases, the antigenic peptides are unknown. In coeliac disease and drug-induced liver injury, equally strong HLA associations are complementary to exogenous gluten and drugs, respectively, suggesting the presence of a similar mechanism behind HLA associations in autoimmunity. 87 Data also suggest the presence of PSC specific TCR clones in the livers of patients, 88 but as for the PSC associated HLA variants, their antigen specificity is unknown. It is currently unknown whether the gut and liver co-morbidity in PSC is caused by exposure to a similar antigenic trigger at both sites, 89 or by the recruitment to the liver of T cells that have been primarily activated in the gut. 90 The latter possibility is favoured by the presence of similar lymphocyte homing mechanisms for the liver and the gut. 91 The predominant cell type in the portal inflammatory infiltrate in liver biopsies from patients with PSC is the T cell. 92, 93 It has been suggested that there is cross-talk between cholangiocytes and T cells, facilitating their recruitment to the portal areas. 94, 95 How the potentially T cell related susceptibility genes (e.g. IL2/IL21, IL2RA, HDAC7, SIK2, PTPN2, SH2B3, CTLA4/CD28, IL2/IL21, MMEL1/TNFRSF14, CCL20, CD226, FOXP1, CCDC88B and PRKD2) exert their pathogenicity in the context of this cellular infiltrate is unknown. Many of them are relevant both to development, activation and key effector functions of several T cell subsets. Other cell types, notably macrophages and neutrophils, are found in the portal areas. 96, 97 By investigating bile, a strong protein signature (e.g. IL8, S100A8), supporting the involvement of one or both of these cell types has been found. [98] [99] [100] Some of the susceptibility genes (e.g. PRDX5, TGR5, PSMG1, NFKB1 and REL) may also play a role in innate immune responses related to these observations, but details are unknown.
Regarding the potential triggering of innate immune responses by gut-derived bacterial components, similar to cholangiopathy in the Cftr À/À mouse model, 101 there is currently limited human data supporting the occurrence of simple ''leakage" of LPS and other bacterial components in PSC. 102 Some of the PSC susceptibility loci harbour genes that are potentially involved in bile acid homeostasis (e.g. TGR5 on chromosome 2 and HDAC7 on chromosome 12), 103, 104 but there is currently no data to support involvement of genes causing Mendelian cholestasis syndromes (e.g. ABCB4 and BSEP) in PSC. This does not mean bile acid toxicity and alterations to protective mechanisms (including the HCO 3 À -producing machinery, which involves both CFTR and TGR5) 19 are irrelevant, but rather it implies such mechanisms are downstream of the initiating events (Fig. 2) . Bile formation is a complex physiological process. 105 A broad avenue of research in the bile acid field has developed in close relationship with therapeutic developments. The widespread prescription of UDCA has inspired research into the mechanisms of action behind the potential protective effects of bile acid interventions in Seminar JOURNAL OF HEPATOLOGY PSC. 106 New therapeutic applications have been derived from this research in the form of norUDCA, which appears to enhance general resistance to bile acid induced biliary injury, via a bicarbonate rich choleresis, along with local effects in the bile ducts by cholehepatic shunting. [107] [108] [109] [110] Additionally, research following the same logic has expanded knowledge on a broad range of nuclear receptors that respond to cholestasis and are involved in normal bile acid homeostasis (e.g. farnesoid X receptor; FXR, retinoid X receptor; RXR, peroxisome proliferator-activated receptor alpha; PPARalpha and pregnane X receptor; PXR). 111 These receptors are currently under scrutiny as therapeutic targets in early phase clinical trials (e.g. trials of the FXR agonist obeticholic acid). The biliary epithelium shows an activated phenotype in PSC, 112 including an expansion of the peribiliary gland system. 113 125, 126 ) influence biliary physiology.
The composition of the gut microbiota in PSC has been described using 16S rRNA sequencing technologies. 20 Overall, the composition of the gut microbial community is altered, with an overall reduction in bacterial diversity and altered abundance of certain bacteria compared with the healthy state. 24, [127] [128] [129] [130] [131] [132] The loss of microbial diversity observed in a variety of disease states, PSC now included, is a major outcome of studies so far. 133 Yet, this observation raises the problem of ''the chicken or the egg", which cannot currently be resolved. To date, most studies performed in human diseases have analysed mucosal or stool samples from diseased individuals, in whom observations can be a consequence, as much as a cause of the disease. However, data from other diseases, suggests that reduced bacterial diversity occurs prior to and independent from clinical disease manifestations. 20 By what mechanisms bacterial diversity and other gut microbial changes may be pathogenic remains to be established for any disease. For PSC, several hypotheses can be made, ranging from immunolog-
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The role of the gut in PSC development is as of yet undefined, and the interplay between the gut microbiota and host immunology and bile acid physiology are rapidly growing research fields. ) is also variable and does not correlate with liver manifestations. Liver disease progression is inevitable in most patients, with fibrosis and cirrhosis due to inflammatory and cholestatic processes (Fig. 2) . As illustrated in the bottom timeline, the high fraction of asymptomatic patients at diagnosis raises suspicion that there is often a long preclinical phase and diagnostic lead-time. The lack of tools to accurately evaluate disease activity and stage in PSC is a challenge in the follow-up of patients and in determining clinical efficacy of new drugs in clinical trials (Table 2 and Box 5). Clinical events frequently warrant specialist consultation (Box 3). Liver transplantation is the only curative treatment option, but timing varies according to local practice, which involves symptomatic indications (e.g. recurrent cholangitis, intractable pruritus) and cholangiocellular dysplasia in addition to end-stage liver disease. Finally, as shown in the right part of the figure, a number of post-transplant issues occur in PSC, including a high frequency of acute cellular rejections, disease recurrence as well as IBD exacerbations (which must be demarcated from transplant related bowel complications, such as cytomegalovirus colitis and mycophenolate colitis). Printed with permission from Kari C. Toverud.
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Seminar ical mechanisms (e.g. altered innate immune activation status, antigenicity of microbial products) to metabolic factors (e.g. relating to bacterial cometabolism of bile acids). Gene findings (e.g. the FUT2 associations 79, 134, 135 ) support the involvement of the gut microbiota in initiating events of PSC pathogenesis, which as suggested from the pilot data on antibiotic therapy may also hold therapeutic prospects. 136 
Diagnostic definitions
A practical guide to diagnostic considerations when PSC is suspected is provided (Box 1). PSC requires a radiological diagnosis made upon the exclusion of known causes of sclerosing cholangitis (secondary sclerosing cholangitis, Box 1). The modality of choice for making a diagnosis of PSC is now MRC, with acceptable sensitivity and specificity (0.86 and 0.94, respectively) and cost-effectiveness compared with ERC for initial screening. 137, 138 Serum liver tests typically show a cholestatic profile, but it is important to be aware that alkaline phosphatase (ALP) levels are naturally fluctuating in PSC (Fig. 4) , and may be normal in a significant fraction of patients. Clinical, endoscopic (i.e. type and distribution of lesions), radiological and histological examinations are required to establish a diagnosis of either UC or Crohn's disease in patients with PSC. 139, 140 The IBD associated with PSC is phenotypically ( Fig. 1 ) and genetically [73] [74] [75] distinct from patients with IBD in the absence of PSC. Since pathognomonic features of IBD in PSC do not exist, standard IBD definitions should still be used, whilst making sure particular features (e.g. ''backwash" ileitis, rectal sparing etc.) are adequately captured and described. Definition of PSC subtypes (Box 1) and CCA (Box 2) often poses similar clinical considerations, since normal diagnostic criteria and definitions are often not directly applicable to patients with PSC.
IgG4-associated sclerosing cholangitis
The distinction between IAC and PSC with elevated IgG4 is important as the cholangiographic changes of IAC may resolve completely upon corticosteroid treatment and IAC is not pre-malignant. However, PSC patients with elevated IgG4 are less responsive and data suggest they may progress more rapidly than other PSC patients. 10, 11 Patients are diagnosed using an adaption of the HISORt criteria for autoimmune pancreatitis, on the basis of two or more main manifestations (elevated serum IgG4, suggestive pancreatic imaging findings, other organ involvement and bile duct/ampullary biopsy with >10 IgG4 positive cells/high power field) combined with a significant response to corticosteroid treatment. 141 
Autoimmune hepatitis in patients with PSC
Biochemical and histological features of autoimmune hepatitis are apparent in 7-14% of patients with PSC. This poorly demarcated patient group has previously been denominated ''overlap patients" or patients affected with ''overlap syndrome". However, current understanding is that rather than reflecting a distinct entity, the observed autoimmune features in PSC form a continuous spectrum with higher activities typically seen in younger patients. 147 Accordingly, a position paper published from the International Autoimmune Hepatitis Group (IAIHG) 148 argues in favour of abandoning the term ''overlap syndrome". Rather, the consensus is that each diagnosis should be considered separately, and a diagnosis of PSC made based on standard criteria. If features of autoimmune hepatitis are also detected, the patient has PSC with features of autoimmune hepatitis. Importantly, diagnosis and treatment of autoimmune hepatitis in the context of PSC is complex and the IAIHG scoring systems for autoimmune hepatitis are less useful. Elevated transaminases and IgG may indicate autoimmune hepatitis, but may also be elevated as part of the biliary disease, meaning histological evidence is generally required for the diagnosis of the combined entity and therapeutic decision-making. Immunosuppressive therapy following standard guidelines for treatment of autoimmune hepatitis is recommended for patients with PSC and features of autoimmune hepatitis, although literature regarding treatment outcome is scarce. 149 The treatment response seems less pronounced than in autoimmune hepatitis without a primary diagnosis of PSC, and the risk of sideeffects, particularly bone disease, often prompts discontinuation in difficult-to-treat cases.
Stratification and prognostication
The natural history of PSC is progressive, evolving through biliary fibrosis to liver cirrhosis and endstage liver disease or CCA in the vast majority of patients (Fig. 4) . 150 156 The PSC specific revised Mayo risk score is the most widely used model (Table 2) ; however, its relatively short horizon (four years), as well as a flat-running survival estimate curve in early-stage disease, yields limited discriminant information. Moreover, the notable failure of the model in forecasting the adverse outcomes observed in high-dose UDCA treatment trials was a disappointment.
The observation that ALP reduction after UDCA treatment can predict outcomes (liver transplantation and death) in PBC 158 has inspired studies into the association between ALP reduction and clinical outcome after UDCA treatment in PSC. [159] [160] [161] [162] [163] However, study design varies and attempts to crossvalidate suggested criteria in subsequent studies have failed. For instance, a cut-off value of 1.5xULN proved discriminatory at two years in one study (Oxford cohort), but was only found predictive when applied at six and 12 months by others (Heidelberg and UK-PSC series, respectively). In addition, unlike in PBC, ALP has a naturally unpredictable fluctuating nature in PSC which, on the individual level, may limit the value of single measurements at any point in time for patient follow-up or clinical trials alike. Thus, further studies are warranted to clarify the relevance of ALP for treatment response stratification in PSC.
As typical cholangiographic changes define the diagnosis of PSC, prognostic scoring systems have been based on imaging of bile duct changes in PSC. The cholangiographic classification of intra-and extrahepatic biliary duct lesions using ERC in the
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Ursodeoxycholic acid has a positive impact on surrogate markers for PSC activity and is widely prescribed for treatment of PSC, but should not be used at high doses. 
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Amsterdam score was proposed to estimate medium-and long-term prognosis in PSC, 164 but the invasive procedure reduces applicability in clinical practice. One study reported that early peribiliary hyperenhancement on MR imaging (MRI) was associated with the Mayo risk score, as well as clinical outcome (liver transplantation-free survival), 165 but others conclude that correlation between MRI/MRC findings and survival is unclear. 166 Liver biopsy offers direct assessment of pathologic processes and traditionally played a central role in the evaluation of PSC, providing histologic assessment of disease grade and stage as gauged by the extent of inflammation and fibrosis, respectively. The Ludwig's score of fibrosis has been regarded as a reference standard in PSC, defining four progressive stages of disease. Histology was included in several early risk models for PSC (Table 2 ) and increasing Ludwig stage is associated with poorer survival. 153 Staging by either of three histological scoring systems: the Nakanuma system (developed for PBC), Ishak scoring, and Ludwig and Batts' scoring, was demonstrated to associate with transplant-free survival. 167, 168 More objective continuous measures of the amount of fibrosis, such as collagen proportionate area may further improve the performance of liver histology, avoiding interobserver variability in the staging of PSC. Histology may be subject to considerable sampling variability in PSC, 169 although the clinical importance of the sampling error is disputed by some. 170 Nevertheless, the invasive nature and associated risk of adverse events, despite low procedurerelated mortality, limit routine applicability of liver biopsy in PSC.
Noninvasive tests
In recent years, there has been much interest in the development of noninvasive tests of liver fibrosis for stratification and prognostication in PSC. Serum tests of liver fibrosis reflect fibrogenesis either indirectly (e.g. APRI, Fib4 score) or directly. The 
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Clinical events and patient management
PSC patients are subject to a number of significant events throughout a fluctuating and highly variable disease course (Fig. 4) . Treatment recommendations are limited by the lack of robust data, but the current consensus is summarised in Box 3. Clinical experience is crucial given the complexity of the condition. We believe gastroenterologists and hepatologists at referral centres, with a significant experience base, should see patients with PSC at least annually and on the development of new symptoms.
Symptoms and quality of life
Approximately 50% of patients with PSC are reported to have symptoms in recently published patient series; however, patient surveys report a higher prevalence, with fatigue, pain and pruritus the most common. 180 A limited number of studies have now been published interrogating the quality of life experienced by patients with PSC, utilising a The onset of acute cholangitis necessitates assessment for flow limiting biliary strictures by MRI and when necessary biliary intervention. Positive bacterial cultures of bile in patients undergoing ERC for dominant stenosis is not associated with worse prognosis in PSC, provided the dominant stenosis and infection are treated. However, Candida infection of bile may be associated with significantly worse prognosis. 192 Occasionally, late-stage patients may require long-term, rotating antibiotics for recurrent cholangitis.
Symptomatic treatment
Clinically apparent recurrent cholangitis may be a debilitating clinical problem for patients with PSC, but it is not associated with a worse prognosis for patients awaiting liver transplant, hence additional exception points are not warranted within MELD-based allocation systems. 193 This has called into question whether recurrent cholangitis should be an accepted indication for liver transplantation given the limited organ supply. There is a wide variation in practice internationally with 17% of patients with PSC transplanted for this indication in Norway, 188 while less than 5% of patients with PSC are registered for this indication in the UK.
Dominant strictures
The term dominant stricture is used to describe a clinically significant stenosis within the extrahepatic biliary tree in PSC detected at ERC. The generally accepted, yet arbitrary, definition is a stenosis of ≤1.5 mm in the common bile duct or ≤1 mm in the hepatic duct within 2 cm of the hilum. 194 Associated jaundice and/or cholestatic liver dysfunction are not part of the definition, although they do indicate the clinical relevance of the stenosis, which justifies invasive evaluation and therapy. 59 The ERC definition of a dominant stricture is not validated for MRC, which lacks hydrostatic pressure and spatial resolution in the extrahepatic ducts. However, MRC offers utility by providing a road map for subsequent ERC and may identify relevant mass lesions. Limited data exist regarding the natural history of untreated dominant strictures. A single retrospective study reporting dominant stenosis in 45% of patients, demonstrated similar change in liver biochemistry from baseline at two months and one year after diagnosis, whether a dominant stenosis was present or not. 195 This suggests that dominant stenoses do not result in worse short-term outcomes and questions whether biliary intervention is justified in the absence of worsening cholestasis. The reported incidence of complications associated with ERC in PSC is 4-18%. [196] [197] [198] [199] [200] [201] In one of three studies that had a control group the incidence of complications was increased compared to patients without PSC. 201 This justifies an approach whereby ERC is undertaken by the most experienced available operator. Peri-procedural antibiotics and standard strategies for prevention of pancreatitis (e.g. rectal NSAIDs and occasional prophylactic pancreatic stenting) are recommended per existing guidelines. 59 For the management of dominant strictures in PSC, balloon dilatation is the approach for which most evidence exists. 202 However, smaller studies report the short-term efficacy of plastic stent insertion (1-2 weeks). 202, 203 In a recent randomised trial, both treatments were of equal clinical benefit, but with more frequent side-effects in the stenting group.
204
Cholangiocarcinoma It can be difficult to distinguish between the symptoms and findings of early stages of CCA complicating PSC, from PSC alone, although in the majority of cases, the early stages of CCA are asymptomatic (Fig. 1) . 205 While rapid deterioration of liver function, abdominal pain, weight loss and increasing jaundice in patients with PSC should elicit suspicion of CCA, equally they may be caused by benign complications or progression of PSC, and when related to malignancy often reflect advanced CCA. Diagnosing CCA in PSC relies on a combination of tumour marker CA19-9, various imaging modalities, biliary brush cytology, including cytogenetic testing if available and histology (Box 2). 56, 57, 206 A utility of CA19-9 is only seen in combination with other modalities, as it lacks sensitivity (low levels may be observed in advanced CCA) and specificity
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Prognostication in PSC is likely to improve upon implementation of noninvasive tests for disease severity and disease stage; elastography and protein markers in particular.
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Seminar (elevated levels may be observed with cholangitis or other malignancies). 207 Genetic variants in the fucosyltransferases 2 and 3 (FUT2/FUT3) influence CA19-9 levels. 208 MRI and computerised tomography may visualise early features of CCA in PSC, but difficulties in distinguishing inflammatory, benign and malignant lesions lead to suboptimal diagnostic accuracy. Combined MRI/MRC has the highest sensitivity (sensitivity 89%, specificity 75%), 205 and is preferred for the detection of small lesions. 209 PET scan does not provide higher diagnostic accuracy in diagnosing early-stage CCA, but can be of value in the staging of CCA diagnosed by another modality. 210 Invasive imaging techniques including ERC, endoscopic extra-or intraductal ultrasound and cholangioscopy are complementary to noninvasive imaging modalities as they afford the opportunity to obtain cytological and histological samples required for definitive diagnosis of dysplasia or CCA in PSC. Endoscopic ultrasound (EUS) with fine needle aspiration has shown utility in establishing the diagnosis of CCA, particularly in patients with negative brush cytology and no mass on cross-sectional imaging, 211 but as for transcutaneous biopsies, concerns have been raised over the risk of needle track tumour cell seeding. For this reason, and based on availability and local experience, practices differ regarding the use of endoscopic ultrasound with tissue sampling. 59 Peroral cholangioscopy using a thin, flexible catheter-type endoscope that allows for direct visualisation of extrahepatic bile duct strictures has shown improved diagnostic accuracy in identifying malignant strictures in sporadic CCA, but focused studies in PSC-CCA have not been performed. 59 The utility of single-operator cholangioscopy (e.g. SpyGlass
Ò
, Boston Scientific, USA) has been evaluated in a case series including 47 patients with PSC, where the procedure enabled targeted biopsies from otherwise inaccessible strictures, but where only one out of a limited number of three patients with CCA were diagnosed by the procedure (sensitivity 33%, specificity 100%). 212 Given limitations in available evidence and availability of EUS and second generation cholangioscopy, ERC with biliary brushings remains the standard for obtaining tissue samples on suspected CCA in PSC (Fig. 5) . While biliary brush cytology has a high specificity (97% in meta-analysis) for malignancy in PSC, it has limited sensitivity (43% in the same series). 213 The addition of fluorescent in situ hybridisation (FISH) for PSC increases the sensitivity (68% in meta-analysis) at the expense of specificity (reduced to 70%). 214 Lack of accurate diagnostic modalities for detection of early stages of CCA (Box 2) and insufficient treatment strategies for advanced stages of CCA currently restrict the ability to perform effective CCA surveillance (Box 4). 215 Clinical practice varies, but proposals advise an interval surveillance strategy with annual MRI or ultrasound in combination with CA19-9 followed up by ERC, with biliary brush cytology and FISH (if available), in cases where there is a suspicion of CCA clinically and/or on imaging. Particular vigilance is required in newly diagnosed patients with PSC. The indication for and timing of liver transplantation in patients with dysplasia and no signs of CCA remain controversial. 56 Presence of dysplasia of any grade has been reported in 83% of explant livers with PSC-CCA, compared with 36% of those without CCA. 216 However, about one-third of patients with biliary dysplasia have been reported not to have CCA on follow-up and the time interval for progression from dysplasia to carcinoma is unpredictable.
216
Liver transplantation or surgery with complete resection represent the only treatments with curative intent for CCA. 217 Liver transplantation follow- 
219-221
Chemotherapy improves the progression-free and overall survival, but the median overall survival is still only approaching one year in metastatic CCA. 219 Other palliative treatment strategies include endoscopic stenting and photodynamic therapy.
222
Cirrhosis
There is presently no medical therapy proven to delay the development of liver cirrhosis in patients with PSC. There has been extensive debate as to the efficacy of UDCA, 56, 57 leading to inconsistent prescription practices around the world. Whilst high-dose UDCA (28-30 mg/kg/day) is likely to be harmful, 157 there is insufficient evidence to argue for or against prescription of low-dose (13-15 mg/ kg/day) UDCA. 223 In some centres, a six month trial period of low-dose (13-15 mg/kg/day) UDCA prescription is utilised, whereby a decrease in ALP levels is used as the basis for potential long-term prescription. 224 Immunosuppression may be efficacious in the subset of patients with concurrent autoimmune hepatitis. However, this is not evidence-based and any observed benefit must be weighed against the risk of side-effects. Paediatric series have documented progression of liver disease in approximately half of patients with PSC and concurrent autoimmune hepatitis. 225 Documented IAC should be treated with corticosteroids, but it is doubtful whether immunosuppression is effective
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Cholangiocarcinoma and colon cancer are dreaded complications in PSC and malignancy is currently the single most common cause of death in patients.
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in patients with PSC, mild elevation of IgG4, and no IAC.
The appearance of the liver on imaging can be very abnormal in PSC, with marked atrophy of a liver lobe (usually the right) and compensatory hypertrophy of the remainder of the liver with regenerative nodules. 226 Hence, making a diagnosis of cirrhosis in PSC has largely been dependent on the finding of clinical and/or imaging features of portal hypertension or the development of complications of cirrhosis. The management and surveillance strategies used for PSC cirrhosis are similar to those used for other causes of cirrhosis and should be undertaken per standard clinical practice and guidelines. That said, the risk of HCC in PSC and PSC cirrhosis appears to be low, raising the question of surveillance intervals in PSC cirrhosis. 60 In addition, newer surveillance strategies for the development of varices dependent on TE cut-offs have not been validated in PSC and monitoring the hepatic venous pressure gradient is not recommended to assess prognosis in cholestatic cirrhosis. The presence of cirrhosis and portal hypertension in PSC may pose significant challenges to the management of associated conditions, e.g. colectomy and surgical resection of CCA.
Liver transplantation
The indications for liver transplantation in PSC are similar to other liver diseases with the majority listed and transplanted with a qualifying MELD (or similar) score in a patient with cirrhosis. 227 256 The reason for this is that the BilIN classification partly accounts for architecture, which cannot be assessed by brush cytology. Furthermore, the reproducibility of brush cytology assessments by Riddel's classification may be better, particularly for less experienced observers. Riddel's classification involves normal epithelium (upper right of top panels), indefinite for dysplasia, low grade dysplasia (lower left of top panels) and high-grade dysplasia (including adenocarcinoma) (bottom panels). As described elsewhere, 256 normal epithelium is comprised of ''cobblestone" sheets of cells in monolayer with even, relatively dense chromatin pattern and no nucleoli. Low-grade dysplasia is characterised by sheets and clusters of cells with nuclear/cellular overlapping (''non-monolayer" growth), smooth nuclear shape and moderately increased nuclear/cytoplasmic ratio. High-grade dysplasia exhibits typical cell clusters with marked increases in nuclear/cytoplasmic ratio, nuclear/cellular overlapping and crowding; the nuclear membranes are irregular with signs of moulding; the nuclei show coarse chromatin with distinct and prominent nucleoli. Upper panel is stained by May-Grünwald-Giemsa, lower panel is stained by Papanicolaou. Printed with permission from Kari C. Toverud.
Seminar liver transplantation is offered to patients with cholangiocellular dysplasia, whilst some US centres undertake liver transplantation for highly selected patients with hilar CCA. An analysis of UNOS outcomes demonstrated that patients with PSC had a lower mortality and were less likely to be removed from the list (too sick) than patients listed for other indications despite similar MELD scores. 228 This suggests that MELD may overestimate the severity of liver dysfunction in patients with PSC. Conversely, it has been argued that whilst MELD predicts waitlist mortality, the actual need for liver transplantation is poorly reflected for some patient groups (PSC included) for which MELD introduces a systematic disadvantage. [228] [229] [230] PSC patients frequently experience a poor quality of life and increased risk of disease-specific adverse outcomes, including recurrent or intractable cholangitis and the development of biliary malignancies, all poorly reflected by MELD-score based risk prediction. 228 Overall <5% of transplants in the US are done on the basis of PSC while about 15% of those in Scandinavia are undertaken for PSC, reflecting both differences in practice and prevalence. Relatively high rates of transplantation for a rare disease like PSC reflect the progressive nature of the condition and the current lack of disease modifying treatments. Patients with PSC experience excellent outcomes after liver transplantation compared to other indications. When compared to other primary liver diseases, patients with PSC achieve the second best life expectancy after transplantation partially accounted for by the younger age of patients with PSC being transplanted. 231 There are a number of specific management issues relevant to patients with PSC through the transplant process, including management of colitis, graft selection, anticoagulation, type of biliary anastomosis and disease recurrence. Pre-operative remission of colitis is recommended, as active disease at transplantation has been reported to predict subsequent graft failure. 232 In the MELD era, patients with PSC in the US have experienced increased waiting times for deceased donor transplantation and more frequently undergo live donor liver transplant (LDLT) compared with other indications. 233 The same group have demonstrated that patients with cholestatic liver disease have better patient and graft survival with LDLT compared to recipients from deceased donors, which would be further enhanced in an intention to treat analysis by accounting for the shorter waiting time afforded by LDLT. 234 Patients with PSC have increased peritransplant hypercoagulability, 235 but the implication of this finding on thrombotic events remains to be established. A further peri-operative consideration is the type of biliary anastomosis, where a trend from hepatico-jejunostomy with a Roux-en-Y towards hepaticoduodenostomy and duct-toduct has been seen. A meta-analysis of published case-control studies suggested lower rates of cholangitis in patients with a duct-to-duct anastomosis compared to patients undergoing a bilioenteric anastomosis. 236 In keeping with other autoimmune liver diseases, early and late cellular rejection are more common after liver transplantation for PSC, 237 hence immunosuppression combining long-term steroids, a calcineurin inhibitor with a third agent (e.g. azathioprine or mycophenolate) is used in many transplant programmes. However, evidence-based guidance regarding the optimal immunosuppressive regimen in PSC is lacking, and informal surveys have revealed large variations in current practice (ranging from mono to triple immunosuppression longterm). With recent advances in HCV treatment, PSC is now the most common disease to recur after liver transplantation. Variable frequencies of recurrent PSC after liver transplantation have been reported in the literature (range 6-60%), however, a frequency of around 20% is most commonly seen. 237 An observation that colectomy prior to liver transplantation is associated with a lower risk of PSC recurrence has been reported from multiple UK centres. 238 Although many other single centre reports have been made, no single factor has consistently been reported to impact on the risk of recurrent PSC. 237, 239 As for PSC per se, no medical
Key point
The optimal regimen for immunosuppression in PSC patients after liver transplantation is not clear, and disease recurrence and IBD exacerbations often occur. 
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interventions are currently available to prevent the progression of recurrent PSC, which is ultimately associated with significantly reduced graft and patient survival.
238
IBD and colorectal neoplasia in PSC PSC-IBD, whether considered UC or Crohn's (Fig. 3) , is almost universally colonic (usually a pancolitis), with a right-sided predominance, backwash ileitis and rectal sparing (Fig. 1) . 240 Thus, a complete ileocolonoscopy is warranted in all patients with PSC. Current guidelines recommend 5-yearly colonoscopies to survey for colitis in patients with PSC and without known colitis, with routine biopsies recommended to increase the detection of IBD. 56, 59 In the absence of more specific guidelines, patients with PSC-IBD should receive medical treatment according to general IBD guidelines. 57 The increased risk of colorectal cancer in PSC-IBD justifies a strict surveillance strategy of yearly colonoscopy from the time of diagnosis for patients with PSC-IBD. 59 Dye-based chromoendoscopy is being increasingly recommended to facilitate detection of flat lesions with dysplasia. 56, 57, 209, 241, 242 In addition to targeted biopsies, non-targeted fourquadrant biopsies from all colonic segments and the terminal ileum should, in general, be performed, but can be omitted in follow-up ileocolonoscopies conducted by appropriately trained hands in the situation of quiescent disease and adequate bowel preparation. 241, 243 Surgical management of PSC-IBD may be required before or after liver transplantation. Both pancolectomy with ileostomy and colectomy with ileal pouch anal anastomosis are feasible and effective. While pouchitis is more common for patients with PSC-IBD, compared to patients with UC alone, 240 
Cause of death in PSC
There was a fourfold increased risk of mortality in patients with PSC compared to the general population in a large population based cohort. 34 The median survival until liver transplantation or PSC-related death in this cohort was of 21.3 years, as opposed to 13.2 years in a tertiary referral cohort from the same geographical area. 34 The most frequent causes of PSC-related death were CCA (32%), liver failure (15%), transplant-related complications (9%) and colorectal cancer (8%), demonstrating that a major impact on life expectancy is imposed by the increased risk of malignancies in PSC.
Summary and future directions
PSC remains a considerable clinical challenge despite the many scientific advances made over recent years. The lack of effective medical therapy to arrest disease and manage symptoms necessitates invasive treatment (endoscopy and liver transplantation) as the mainstays of management. Co-morbidities add to disease burden, particularly IBD and the unpredictable risk of cancer. Diagnostic tools to gauge disease activity and cholangiocellular dysplasia would be extremely helpful, but are currently in their infancy. Research is needed in many areas, including biliary and bowel complications after liver transplantation. These unmet needs make PSC one of the major remaining challenges in hepatology. Whilst genetic studies have positioned PSC alongside other autoimmune diseases, the translational value of this observation remains unclear. The possibility of an environmental driver of the autoimmune features, similar to coeliac disease, remains a possibility. 87 PSC-centred studies on the individual gene findings are awaited to clarify whether the wealth of biologics currently available for other autoimmune and immune-mediated diseases might hold re-purposing opportunities in PSC. It is a time of particular activity for clinical trials in PSC with the majority of clinical trials focussed on cholestatic and fibrotic targets (e.g. norUDCA, anti-LOXL2, obeticholic acid and other FXR agonists, ASBT inhibition), with some emerging interest in therapeutic targeting of the gut microbiota (e.g. faecal transplantation, long-term non-absorbable antibiotics) and T lymphocyte homing (e.g. anti-VAP1, vedolizumab). The norUDCA phase II trial demonstrated a dose-dependent reduction of ALP in patients receiving 500-1500 mg norUDCA compared with placebo. 247 The results from the simtuzumab trial have been published in abstract form and were essentially negative. 248 The effects of the other interventions are currently unknown. As shown in Fig. 2 , the complex multistep process ultimately resulting in PSC is likely to involve all aspects currently being targeted. The outcomes of the ongoing clinical trials may help determine which principle approaches are likely to be most effective. The different pathophysiological components may also need targeting in parallel for efficacy to be obtained, meaning that ultimately a combination of conceptually different drugs is potentially needed. We can only predict incremental discoveries in science. In the near future, implementation of biomarker research and advances in imaging technologies (both MRI and ultrasound) are likely to address major limitations related to diagnosis, prognostication, surveillance and the gauging of treatment effects in PSC. Studies of the gut microbiota in PSC are rapidly evolving, 20 and are likely to open up major new areas of research, improving our understanding of PSC pathophysiology. Game-changing discoveries will elucidate the causes of PSC and its associated malignancies, but where among the candidate areas (Fig. 2 ) such discoveries should be sought is speculation. Together, the many challenges create considerable research opportunities for clinical and basic scientists alike, and will keep a small and enthusiastic specialist community busy for years to come.
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